Bosutinib (SKI-606) Licensed by Pfizer

Catalog No.S1014

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7NH7JfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTBwMEiyN|EhKM7:TR?=MX7TRW5ITVJ?
SW756MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;TXGlEPTB;MD6xOFAzPCBizszNMkjlV2FPT0WU
CTV-1MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTBwMU[zPVghKM7:TR?=MW\TRW5ITVJ?
HSC-4NFPTRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPDZW1MUUN3ME2wMlE4OTV6IDFOwG0>MWHTRW5ITVJ?
LAMA-84NH\0c|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;YPWlEPTB;MD6yPFY3PCBizszNMXrTRW5ITVJ?
KU812M3vsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17FTGlEPTB;MD6zOFA3QCBizszNNWjCVGNXW0GQR1XS
HCC1806MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjobnBKSzVyPUCuN|UzOTZiIN88US=>NFj3TZdUSU6JRWK=
DOKM2TBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrkTWM2OD1yLkO3O|g3KCEQvF2=Mnz3V2FPT0WU
NCI-H209Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTBwNEC4NFghKM7:TR?=NHW1dYFUSU6JRWK=
EoL-1-cellNVn5V|c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm[5TWM2OD1yLkSxOVc3KCEQvF2=NUiyOIlNW0GQR1XS
H9MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nSfmlEPTB;MD60N|Q3PCBizszNMn20V2FPT0WU
EM-2Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILhSppKSzVyPUCuOFM5QSBizszNMVLTRW5ITVJ?
NCI-H292MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTBwNESxNFghKM7:TR?=NFPTO2xUSU6JRWK=
697M3XpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXyTWM2OD1yLkS1OlM{KCEQvF2=MoK2V2FPT0WU
BHT-101MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4foUWlEPTB;MD60OlU6KCEQvF2=MWLTRW5ITVJ?
BE-13NELCZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHXU5NnUUN3ME2wMlQ5PTd{IDFOwG0>NWKzdnczW0GQR1XS
RS4-11MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\sfGlEPTB;MD60PFU5PCBizszNNEXNXmRUSU6JRWK=
IGROV-1NIfQdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTBwNEi3PVchKM7:TR?=NFOyO3FUSU6JRWK=
KE-37M2H2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvmTWM2OD1yLkS5OVA6KCEQvF2=Mln1V2FPT0WU
BV-173Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnHSZFnUUN3ME2wMlUxPzl{IDFOwG0>NIj5WllUSU6JRWK=
MEG-01NIXN[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2SwWGlEPTB;MD61NVIyPCBizszNMX\TRW5ITVJ?
LB2241-RCCNFXOVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUj6XXY2UUN3ME2wMlU{PzF6IDFOwG0>MXHTRW5ITVJ?
ACHNNWr0ZYVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorXTWM2OD1yLkW0NFY6KCEQvF2=M1zUXXNCVkeHUh?=
CTB-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTBwNUS4NkAh|ryPM4nGNnNCVkeHUh?=
HT-1080NHixdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Tze2lEPTB;MD61OVM1QSBizszNMVTTRW5ITVJ?
CHL-1NWDOdpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXDTWM2OD1yLkW1OFY2KCEQvF2=NHrodWVUSU6JRWK=
EW-3MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF:4OGFKSzVyPUCuOVU6OzViIN88US=>M2DyXnNCVkeHUh?=
ES1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvxTWM2OD1yLk[3OFk5KCEQvF2=NIO5U3pUSU6JRWK=
KASUMI-1NY\4O|RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTBwN{KzN{Ah|ryPMXrTRW5ITVJ?
SW13MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEWxR4xKSzVyPUCuO|M4QThiIN88US=>NEn6e5ZUSU6JRWK=
A3-KAWNUjGUGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXmTWM2OD1yLke5NlA5KCEQvF2=NV23VINNW0GQR1XS
LB771-HNCMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLNR5VKSzVyPUCuPFMyODRiIN88US=>Mnv5V2FPT0WU
OC-314M2\Ecmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUK1W|RkUUN3ME2wMlg3QTZ3IDFOwG0>NGXx[mNUSU6JRWK=
MLMAMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTBwOUC2O|UhKM7:TR?=MYTTRW5ITVJ?
KARPAS-45M4rvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLqdGNKSzVyPUCuPVI1PjZiIN88US=>MmK4V2FPT0WU
CAL-27MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTkTWM2OD1yLkmyPVA3KCEQvF2=MUDTRW5ITVJ?
SK-NEP-1Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTBwOUeyOFghKM7:TR?=NX7OeXJVW0GQR1XS
COR-L105M3P1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmj1TWM2OD1zLkCwN|k1KCEQvF2=NXvnZ3J6W0GQR1XS
TI-73MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\2c2lEPTB;MT6wNVY2KCEQvF2=M3vBN3NCVkeHUh?=
JVM-3MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPaTWM2OD1zLkC1NFE4KCEQvF2=M3jFV3NCVkeHUh?=
HAL-01NV\wTo9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnlZnhKSzVyPUGuNFg5OSBizszNMkiyV2FPT0WU
QIMR-WILNU\iW3JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTFwMEmwOVghKM7:TR?=M2LBOXNCVkeHUh?=
HSC-3MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXFc21yUUN3ME2xMlEyPzh|IDFOwG0>MmrMV2FPT0WU
KY821MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2K4UmlEPTB;MT6xN|M2OSBizszNMXHTRW5ITVJ?
5637NFPsflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXf5fWY4UUN3ME2xMlE{QDB|IDFOwG0>NEL0TYdUSU6JRWK=
CAL-33MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLTWGU6UUN3ME2xMlE6OzB{IDFOwG0>MnXGV2FPT0WU
ES4MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mor4TWM2OD1zLkKwO|khKM7:TR?=MX3TRW5ITVJ?
BHYM1fmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkL1TWM2OD1zLkKyPFkzKCEQvF2=NIHEcWVUSU6JRWK=
LB1047-RCCNET2So1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH:4dGZKSzVyPUGuNlM4QDViIN88US=>MULTRW5ITVJ?
H4MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2ewVmlEPTB;MT6yOFI2PSBizszNM4njfXNCVkeHUh?=
RPMI-8866NUfvWldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnwbVFKSzVyPUGuNlYyODZiIN88US=>NGHl[o1USU6JRWK=
HO-1-N-1NGrm[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjIWVZKSzVyPUGuNlY{PjliIN88US=>NVPtUpFTW0GQR1XS
BB30-HNCMnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTFwMki3NVQhKM7:TR?=NWfUeI97W0GQR1XS
PC-14NFyybI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vW[GlEPTB;MT6yPVIxPSBizszNNVnwZoZHW0GQR1XS
NUGC-3M2HTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn75TWM2OD1zLkK5N|U3KCEQvF2=NIG1ZpJUSU6JRWK=
A4-FukMmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33LNGlEPTB;MT6zNFcxPCBizszNMY\TRW5ITVJ?
MHH-NB-11M2jS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7mTWM2OD1zLkOxN|g{KCEQvF2=MnPOV2FPT0WU
KOSC-2NHjlSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\NXWMzUUN3ME2xMlMyPzd3IDFOwG0>MYfTRW5ITVJ?
A498NIjmV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTFwNECxNVMhKM7:TR?=MnXwV2FPT0WU
KG-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXkTWM2OD1zLkSxNlc{KCEQvF2=NEDXeVNUSU6JRWK=
DELMoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLqTWM2OD1zLkSzOlU4KCEQvF2=NGjiNHJUSU6JRWK=
EW-16NV7rPIFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTFwNEO5O|MhKM7:TR?=MYPTRW5ITVJ?
BPH-1NXvKRZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLibmJKSzVyPUGuOFQ5ODViIN88US=>NVvoUGtuW0GQR1XS
JARNHvzTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4mxXmlEPTB;MT60PVM3KCEQvF2=MnrBV2FPT0WU
J-RT3-T3-5M4[yR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnrcGN6UUN3ME2xMlUyPzJ{IDFOwG0>MUnTRW5ITVJ?
A375NUnPUlhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTFwNUG3O|IhKM7:TR?=NXr0NFY2W0GQR1XS
SW954NE\w[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PrcWlEPTB;MT61OVAxPyBizszNM1j3eXNCVkeHUh?=
Ca9-22M{LsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\wNGM3UUN3ME2xMlU3OjZiIN88US=>Mm\vV2FPT0WU
D-566MGMmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;OVW5KSzVyPUGuOVcyPTViIN88US=>NHn0OmZUSU6JRWK=
SCC-15NWHXNmV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml2zTWM2OD1zLk[xPFA1KCEQvF2=M33yPHNCVkeHUh?=
HD-MY-ZNGP2ZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHyOGxKSzVyPUGuOlM2QDRiIN88US=>NIX1PWZUSU6JRWK=
HT-1376NWHlZWlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnX0TWM2OD1zLk[0N|YhKM7:TR?=NXjGZXB1W0GQR1XS
CAL-54NF7yXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3O3O2lEPTB;MT62OVcxQSBizszNMnPaV2FPT0WU
ONS-76NEnzRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nROWlEPTB;MT62O|U2OSBizszNMULTRW5ITVJ?
EFO-27MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITyXoFKSzVyPUGuOlg6OiBizszNNUTnOZdOW0GQR1XS
769-PMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEflcXlKSzVyPUGuOlk2QTZiIN88US=>NF3yPHlUSU6JRWK=
MV-4-11M2K3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrqTWM2OD1zLk[5PFU3KCEQvF2=MoOzV2FPT0WU
NKM-1NXXL[Jd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHldFFKSzVyPUGuO|E5ODJiIN88US=>M2[yRXNCVkeHUh?=
LOXIMVINIK2NopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4SwdWlEPTB;MT63OFU6QSBizszNNUn0WmRMW0GQR1XS
KYSE-140M2fLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XYOWlEPTB;MT63OVY2PSBizszNMli4V2FPT0WU
ES5NF;LWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTFwOE[3OFchKM7:TR?=NV\ZfFhMW0GQR1XS
BB65-RCCMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XDTWlEPTB;MT64PVg1QSBizszNNHrWSmxUSU6JRWK=
HNMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHSW5ZKSzVyPUGuPFk5PzRiIN88US=>M3S2R3NCVkeHUh?=
A101DMoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1m0b2lEPTB;MT65N|YzQCBizszNMkL6V2FPT0WU
LoVoMl\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnS3TWM2OD1zLkm3Olc6KCEQvF2=NEDDcZBUSU6JRWK=
NCI-H526Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTFwOUmzNlUhKM7:TR?=M4HHPHNCVkeHUh?=
NCI-H1693NXfFeZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\jWGlEPTB;MT65PVg5QCBizszNM3WxdHNCVkeHUh?=
OVCAR-4MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjHTWM2OD1{LkCwOFM2KCEQvF2=MkP2V2FPT0WU
SK-HEP-1NGm5S|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVznUHFJUUN3ME2yMlAxPzR3IDFOwG0>NXv1d5llW0GQR1XS
C2BBe1M3PBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTPUYFKSzVyPUKuNFM{PzJiIN88US=>M3rseHNCVkeHUh?=
MEL-JUSOMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDQTWM2OD1{LkC0OFY1KCEQvF2=Mn7FV2FPT0WU
MOLT-16MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTJwMEewOVghKM7:TR?=MlftV2FPT0WU
NBsusSRMl2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIn4VIFKSzVyPUKuNFk5QDliIN88US=>M{KyTnNCVkeHUh?=
TK10NHrmWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3flcmlEPTB;Mj6xN|Q2QCBizszNMoHMV2FPT0WU
CAL-39NFLqW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;iSlVKSzVyPUKuNVQ1QCBizszNNW\UfWJMW0GQR1XS
NCI-H2030NEHFfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\meGlEPTB;Mj6xPFk4OyBizszNMXjTRW5ITVJ?
HCT-116MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDqTWM2OD1{LkKyPVg1KCEQvF2=M4DGRXNCVkeHUh?=
HTC-C3NUi4fI1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvZdGJKSzVyPUKuNlY5OjRiIN88US=>M1TJcHNCVkeHUh?=
TYK-nuNGLKWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJwM{C5NFkhKM7:TR?=M4HhWHNCVkeHUh?=
FADUM37Ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDFTWM2OD1{LkOyNlk3KCEQvF2=MnfOV2FPT0WU
A431NHPVdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmT6TWM2OD1{LkO3NFI2KCEQvF2=NYewdGZmW0GQR1XS
TE-11MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTJwM{iwNVkhKM7:TR?=M2XpTnNCVkeHUh?=
CAL-12TNGrjdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TGdmlEPTB;Mj60NFQyPyBizszNM2HjXHNCVkeHUh?=
DBNGPvSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;YTWM2OD1{LkSyPFY6KCEQvF2=NGK1[VJUSU6JRWK=
L-363MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTJwNEO1NFchKM7:TR?=NFnCdGxUSU6JRWK=
MSTO-211HMoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PwTWlEPTB;Mj62OlM6OSBizszNNH3mT4lUSU6JRWK=
SK-UT-1NYPNTpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUC1bFZNUUN3ME2yMlcyPDB4IDFOwG0>M{\KcHNCVkeHUh?=
RPMI-8226MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvqRYdKSzVyPUKuO|MyPjRiIN88US=>M3nvW3NCVkeHUh?=
SF295MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTUTWM2OD1{Lke0N|EhKM7:TR?=NXPzfJV6W0GQR1XS
OS-RC-2Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;YSWh2UUN3ME2yMlc3Pjd|IDFOwG0>Mn;3V2FPT0WU
SK-MEL-24M2f3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HpemlEPTB;Mj63PFIzPCBizszNNGfVT5FUSU6JRWK=
COR-L23MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJwN{m0OlQhKM7:TR?=NUTleYtIW0GQR1XS
MHH-PREB-1M120T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1:5RWlEPTB;Mj64NFE3OSBizszNM{XNV3NCVkeHUh?=
SK-N-DZNH;rWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjsTWM2OD1{LkixOlM5KCEQvF2=NH2yZnBUSU6JRWK=
OMC-1NVT4SIxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTJwOEWwNFMhKM7:TR?=NGDERmFUSU6JRWK=
SK-MEL-2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXkTWM2OD1{Lki5NlQ{KCEQvF2=NW\DXop{W0GQR1XS
SASNVzMSoVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[yTWM2OD1{Lkm5OFE2KCEQvF2=MVrTRW5ITVJ?
EPLC-272HMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPUZ4wxUUN3ME2zMlAxOjN3IDFOwG0>NFHxbVdUSU6JRWK=
8505CM1H1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TmPWlEPTB;Mz6xNFMxOSBizszNMlnWV2FPT0WU
EW-11Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnP2TWM2OD1|LkG0Nlc4KCEQvF2=MonuV2FPT0WU
YKG-1MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHf4NY9KSzVyPUOuNVQ4ODZiIN88US=>NVn1eIF7W0GQR1XS
EC-GI-10M{DXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nLVGlEPTB;Mz6xO|I3OyBizszNM{X4VnNCVkeHUh?=
SK-LU-1NXnCN|ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHwSnJKSzVyPUOuNVg1OThiIN88US=>NWfQNHNlW0GQR1XS
P30-OHKNUnifJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1G5UmlEPTB;Mz6yNFEyPyBizszNMnvWV2FPT0WU
T-24MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nvWmlEPTB;Mz6yNVgyPCBizszNNUSw[WNzW0GQR1XS
HSC-2NWrEXlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPQOJhKSzVyPUOuNlIzOzJiIN88US=>MWrTRW5ITVJ?
SK-MES-1NEW5[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVL6WYNwUUN3ME2zMlI1QDJ7IDFOwG0>NHPtNFNUSU6JRWK=
SW48MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTNwMkW0PFYhKM7:TR?=MWPTRW5ITVJ?
ME-180MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHS5N2VKSzVyPUOuNlYxPTFiIN88US=>MXHTRW5ITVJ?
NCI-H2009MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1S1fmlEPTB;Mz6yPVAyKCEQvF2=MVnTRW5ITVJ?
HL-60MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2e2ZmlEPTB;Mz6yPVE{KCEQvF2=NEO3PItUSU6JRWK=
NCI-N87M{excGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrJTWM2OD1|LkOwNVczKCEQvF2=NE\sZZNUSU6JRWK=
GMS-10NFzpTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTNwM{SwPFYhKM7:TR?=NULvOYx6W0GQR1XS
SCHNWTLXWdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTFTWM2OD1|LkSwPFQ1KCEQvF2=NXnCO|VsW0GQR1XS
C-33-AM2jx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{O1T2lEPTB;Mz60NVQzOSBizszNM{jFRnNCVkeHUh?=
NCI-H1703MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnG3TWM2OD1|LkSxPFEzKCEQvF2=MXvTRW5ITVJ?
A427MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml:1TWM2OD1|LkS2NVI1KCEQvF2=NVG5RpFuW0GQR1XS
MOLT-4MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HwZmlEPTB;Mz60PFE6QSBizszNMVHTRW5ITVJ?
NCI-H1792M3fhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTNwNEm4NFIhKM7:TR?=MlzTV2FPT0WU
NCI-H1650M3TGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2i2SmlEPTB;Mz61O|I6KCEQvF2=MUDTRW5ITVJ?
H-EMC-SSMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHINJZzUUN3ME2zMlU5PTZ7IDFOwG0>MVvTRW5ITVJ?
SW982MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rpSWlEPTB;Mz61PFgzQSBizszNNHzqU3FUSU6JRWK=
DSH1Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXhTWM2OD1|Lk[0NVIzKCEQvF2=MXPTRW5ITVJ?
NOS-1M3zNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfxUItKSzVyPUOuOlQzPzZiIN88US=>MkLMV2FPT0WU
BT-549MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTNwNke4OVQhKM7:TR?=NXLGNHpQW0GQR1XS
HuCCT1NUnMNpdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTVXGN7UUN3ME2zMlc1OTd5IDFOwG0>NV7FTW9WW0GQR1XS
NCI-H1755Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlT1TWM2OD1|Lkm2PVcyKCEQvF2=M1i4XXNCVkeHUh?=
KYSE-450NGq0RXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGOxbINKSzVyPUOuPVY6QTdiIN88US=>NX;BOXBqW0GQR1XS
MIA-PaCa-2MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;JTWM2OD1|Lkm3NlkhKM7:TR?=M3v6XXNCVkeHUh?=
U-266NX3U[2xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnB[GhkUUN3ME2zMlk4PDhzIDFOwG0>NHHlfppUSU6JRWK=
MewoM4\wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzReJdKSzVyPUSuNFY{PjFiIN88US=>NXLKZnJkW0GQR1XS
KYSE-520MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHGTWM2OD12LkC5O|k6KCEQvF2=NIW4d5hUSU6JRWK=
MN-60NHrWSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\5cYF{UUN3ME20MlExPTBzIDFOwG0>NGDpRphUSU6JRWK=
Ramos-2G6-4C10MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHOcVhKSzVyPUSuNVY4OzliIN88US=>MV7TRW5ITVJ?
SK-MEL-1NFewUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\oWmozUUN3ME20MlE5Pjl3IDFOwG0>NFP2XGFUSU6JRWK=
ABC-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlS2TWM2OD12LkKzN|M{KCEQvF2=Mk\nV2FPT0WU
CAKI-1MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTsWmFKSzVyPUSuNlQ2PzFiIN88US=>MkfTV2FPT0WU
HOSM4Licmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HxbGlEPTB;ND6yPVE1OSBizszNMnrQV2FPT0WU
SN12CNWHGNXhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnTR|BvUUN3ME20MlM1OjR2IDFOwG0>NWe5d3Z1W0GQR1XS
NB13NWfqfpZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HzRmlEPTB;ND6zO|M2PSBizszNMXzTRW5ITVJ?
M14NH7VS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTRwNEi3PVIhKM7:TR?=MVHTRW5ITVJ?
GP5dM{XQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFKxPWlKSzVyPUSuOVAyOiBizszNM13zb3NCVkeHUh?=
NCI-H720MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFP5XmpKSzVyPUSuOVM3OTJiIN88US=>NH;DWIhUSU6JRWK=
D-423MGNFfOV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTRwNUO5NlQhKM7:TR?=MnjxV2FPT0WU
ChaGo-K-1NI\GUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTRwNUm1OVkhKM7:TR?=MorrV2FPT0WU
MEL-HOM1ixV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknNTWM2OD12Lk[xNlYyKCEQvF2=MnqzV2FPT0WU
MHH-ES-1M1iy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHH4VHFKSzVyPUSuOlI1OTFiIN88US=>MkXiV2FPT0WU
KYSE-270NXrEPXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTRwNkWxNlYhKM7:TR?=M4fLWnNCVkeHUh?=
GI-ME-NMnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHW0NnNKSzVyPUSuO|EzQTFiIN88US=>MW\TRW5ITVJ?
HOP-92MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTRwOEGzO|khKM7:TR?=NXH1UmR{W0GQR1XS
MKN1NX;XNpc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17w[mlEPTB;ND64N|kyPCBizszNNXnEcWpbW0GQR1XS
ML-2M3jRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2CxdWlEPTB;ND64OVYzPiBizszNMXPTRW5ITVJ?
RO82-W-1NGrDWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnxXWJKSzVyPUSuPVI6QCBizszNMl32V2FPT0WU
G-361NYS4bG5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjNZXVKSzVyPUWuNFExODNiIN88US=>NVHsdY1nW0GQR1XS
HC-1M1W2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPPOZRKSzVyPUWuNFMzQTFiIN88US=>M1yyXnNCVkeHUh?=
EW-24NYrXU5VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jhdGlEPTB;NT6wOFA{QCBizszNMUfTRW5ITVJ?
HuP-T4NE[x[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\GXGRoUUN3ME21MlE1OzN2IDFOwG0>NVvaWI17W0GQR1XS
8-MG-BAMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHqxbpVKSzVyPUWuN|QzQCBizszNMVHTRW5ITVJ?
HGC-27MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTVwM{e2PFIhKM7:TR?=M1LjVnNCVkeHUh?=
TE-12NXzqXJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDSWZBKSzVyPUWuOFE2QDViIN88US=>MV\TRW5ITVJ?
GT3TKBMlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTVwNESyNVIhKM7:TR?=NXuweGdRW0GQR1XS
DOHH-2NGPSb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;mUIZKSzVyPUWuOFU6QDZiIN88US=>NHjKZZpUSU6JRWK=
Ca-SkiNIrORZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnwV3FKSzVyPUWuOFYyOTViIN88US=>MkTyV2FPT0WU
A172MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDJe5RKSzVyPUWuOVQ6OjViIN88US=>MlGzV2FPT0WU
EGI-1NGLRUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlG1TWM2OD13LkW4PVM5KCEQvF2=NH3nNVhUSU6JRWK=
MZ2-MELNWixfXJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;zTWM2OD13Lk[xOFg3KCEQvF2=NUXEXZM5W0GQR1XS
SW1710Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTVwNkmwPVEhKM7:TR?=M2DQUnNCVkeHUh?=
HT-144NFzJ[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PmNWlEPTB;NT63NlY5PSBizszNNHvwZWpUSU6JRWK=
PA-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEL4VopKSzVyPUWuPFE5QTNiIN88US=>M1yzVnNCVkeHUh?=
HCC1937M1rEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmX5TWM2OD13LkizPVI6KCEQvF2=MVHTRW5ITVJ?
SK-OV-3NUD2bo1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTGeXVsUUN3ME21MlkyOTJzIDFOwG0>Ml7HV2FPT0WU
K5NIXDfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUf0dJBnUUN3ME22MlA2OTdiIN88US=>MlnrV2FPT0WU
NMC-G1M4TMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjsVpJXUUN3ME22MlA4Pzl5IDFOwG0>NUXiNpI{W0GQR1XS
MDA-MB-361M1HYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTZwMEmyOlEhKM7:TR?=MXLTRW5ITVJ?
EKVXMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjqTWM2OD14LkGzOVAyKCEQvF2=NYjnSIgyW0GQR1XS
ES7NIToeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\yUJFKSzVyPU[uNVYyOTViIN88US=>MYfTRW5ITVJ?
KS-1NILsR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnO1TWM2OD14LkG3PVk{KCEQvF2=MXrTRW5ITVJ?
NCI-H661MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnhfHdKSzVyPU[uNVgxQDFiIN88US=>M2HxNHNCVkeHUh?=
ES8NHSzU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\XfGlEPTB;Nj6xPFA5OiBizszNNXLkNZdZW0GQR1XS
NCI-H23MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rwO2lEPTB;Nj6yNVgyPiBizszNNETR[INUSU6JRWK=
T47DM1XRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmH3TWM2OD14LkK2OFU4KCEQvF2=NF;WUlFUSU6JRWK=
A2780NGTpe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULLOHZlUUN3ME22MlM4PzBzIDFOwG0>NU\xR3IzW0GQR1XS
SCC-4MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTZwNEO1OlEhKM7:TR?=MVHTRW5ITVJ?
VA-ES-BJNIrVU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3wd|drUUN3ME22Mlk4ODR|IDFOwG0>MlToV2FPT0WU
no-11MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkX1TWM2OD15LkG2OFEhKM7:TR?=MVXTRW5ITVJ?
KU-19-19NYPBbGdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnLWmVKSzVyPUeuNVY1PzZiIN88US=>M4fRV3NCVkeHUh?=
MKN45NVn6NGdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVmwZ4p{UUN3ME23MlE5Pjl7IDFOwG0>MWnTRW5ITVJ?
SCC-25MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHsPYVKSzVyPUeuNlM1OTRiIN88US=>MkezV2FPT0WU
ETK-1NW\PfHJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIr6[VFKSzVyPUeuNlU2OTRiIN88US=>MVjTRW5ITVJ?
COR-L88NITWb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTdwMkmzNVkhKM7:TR?=MWPTRW5ITVJ?
8305CNELqPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTdwM{K0PVIhKM7:TR?=M{G2b3NCVkeHUh?=
Detroit562NWHBXI9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17rZ2lEPTB;Nz6zNlUxPiBizszNMVnTRW5ITVJ?
SNU-449MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjZWnVKSzVyPUeuN|c3PTFiIN88US=>MVHTRW5ITVJ?
A704MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnTNWlEUUN3ME23MlM5Ojd6IDFOwG0>Ml\iV2FPT0WU
D-502MGNHe0WI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUH6OGdVUUN3ME23MlM5PDd|IDFOwG0>M4Pie3NCVkeHUh?=
NCI-H2228MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PXTWlEPTB;Nz60NVQ2QCBizszNMkC1V2FPT0WU
CHP-212NXO3dZA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;JTWM2OD15LkWxPFk3KCEQvF2=Mme4V2FPT0WU
VMRC-RCZNEP4eJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nZRmlEPTB;Nz61PVA3PiBizszNNGfxeJhUSU6JRWK=
RPMI-2650NHW4S49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TL[WlEPTB;Nz63NFMyOiBizszNM1\IVHNCVkeHUh?=
HCC2218MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPxXYh{UUN3ME23MlczOjV6IDFOwG0>MmD1V2FPT0WU
GCTMn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fxSmlEPTB;Nz64NlE4OiBizszNMoe3V2FPT0WU
SW780NWjacHRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfudYM4UUN3ME23Mlk6ODZiIN88US=>NF;MOHhUSU6JRWK=
KMOE-2MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRThwMESwO{Ah|ryPMXfTRW5ITVJ?
KYSE-180M{DQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWOxOmE1UUN3ME24MlA5PjR6IDFOwG0>MYrTRW5ITVJ?
TE-1NFzlelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFK5XlFKSzVyPUiuNVExPTdiIN88US=>NGG4XHVUSU6JRWK=
OAW-42NHTWdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRThwMkW0PVYhKM7:TR?=NHzjNZNUSU6JRWK=
VM-CUB-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjwOGpoUUN3ME24MlI5OzZ2IDFOwG0>NU[2ZXEzW0GQR1XS
ECC10NF2xWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRThwMkizPVchKM7:TR?=MX3TRW5ITVJ?
SW1573MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfIOFVKSzVyPUiuOFQ1PjViIN88US=>M1;lb3NCVkeHUh?=
NCI-H1299NIHodoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NED4b4hKSzVyPUiuOVk4PzRiIN88US=>NETpRnNUSU6JRWK=
ALL-PONGCxSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRThwNk[1PVchKM7:TR?=NVW0OGloW0GQR1XS
OVCAR-5M{njOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPhZ5VKSzVyPUiuO|c3OjViIN88US=>NInEdVBUSU6JRWK=
NCI-SNU-5MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmf5TWM2OD16LkizNFAyKCEQvF2=NIL5[ZBUSU6JRWK=
NCI-H2342MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRThwOEOxNFEhKM7:TR?=NXXO[mxjW0GQR1XS
RPMI-7951NIfGbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWX4[HgzUUN3ME24Mlg1OTV5IDFOwG0>M{fWRnNCVkeHUh?=
RCM-1NWrmVJVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTlwMEixOFUhKM7:TR?=NVyxfFRrW0GQR1XS
DaoyNWjFTWlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULQbGxjUUN3ME25MlEzODJ6IDFOwG0>NX;WPWNyW0GQR1XS
HCC1395MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFu1fplKSzVyPUmuN|A5QTZiIN88US=>NYHPUHpCW0GQR1XS
786-0MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3njRWlEPTB;OT6zOlAzPiBizszNM2fY[HNCVkeHUh?=
GAMGMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTlwNkW1N|QhKM7:TR?=M37GO3NCVkeHUh?=
HCC1954MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rRZmlEPTB;OT64OVg2QSBizszNNUjqRnV[W0GQR1XS
NCI-H1838MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG[5PVNKSzVyPUmuPVA{PzFiIN88US=>NXrRXIREW0GQR1XS
SW620NVPhRXdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHjUnBKSzVyPUmuPVU{PTdiIN88US=>MljBV2FPT0WU
NCI-H358NUCwcJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTFyLkSxPVchKM7:TR?=MoPiV2FPT0WU
NCI-H1793MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnOcFZbUUN3ME2xNE41OjR6IDFOwG0>NGHqSGJUSU6JRWK=
NCI-H1666NGnoTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTOem1KSzVyPUGwMlQ{PTViIN88US=>NV3wRZVVW0GQR1XS
MZ7-melMkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\PW3hHUUN3ME2xNE41PzV|IDFOwG0>NUnuT3dKW0GQR1XS
MDA-MB-175-VIINUjZb2x[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrvNpBKSzVyPUGwMlY{QTZiIN88US=>NILDSFRUSU6JRWK=
COLO-829MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTFyLkiwNFQhKM7:TR?=NGjjNnFUSU6JRWK=
RVH-421NUm1fFFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PLb2lEPTB;MUGuNVUzKCEQvF2=MlvOV2FPT0WU
A549NF3OXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTFzLkK0O|ghKM7:TR?=M1TFenNCVkeHUh?=
DJM-1NU\ZUIVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTTNFlxUUN3ME2xNU4{QDN|IDFOwG0>NVXMR2VZW0GQR1XS
IST-MEL1NX;rOHA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHrTYhKSzVyPUGxMlc{OTliIN88US=>MWTTRW5ITVJ?
BENNX7hbVdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7vTWM2OD1zMT63OFAzKCEQvF2=MlnVV2FPT0WU
KM12NUnL[|JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTFzLkmwPVEhKM7:TR?=M4HBRXNCVkeHUh?=
HuO9MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[yVYZKSzVyPUGyMlA3PjZiIN88US=>NIfMSJFUSU6JRWK=
U-2-OSNFrtbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\PTWM2OD1zMj6wPFk{KCEQvF2=MlfRV2FPT0WU
RH-1NXjETIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWmzepI5UUN3ME2xNk41PDd{IDFOwG0>MXzTRW5ITVJ?
NCI-H1048MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTJTVlMUUN3ME2xNk42PTB4IDFOwG0>NF7ITmRUSU6JRWK=
Mo-TM3O5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTF{LkezNFchKM7:TR?=M3LQTnNCVkeHUh?=
KYSE-150NVfOT|NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jRemlEPTB;MUKuO|Q2PSBizszNMV;TRW5ITVJ?
A388NVfHcXdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3e3c2lEPTB;MUKuO|cyOyBizszNNXXJVINbW0GQR1XS
NCI-SNU-1NEPwTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\PSXBEUUN3ME2xNk45ODR4IDFOwG0>NW\udJNyW0GQR1XS
HELMorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHe0VXpKSzVyPUGyMlgzOTJiIN88US=>NWHI[lkyW0GQR1XS
UM-UC-3M4H2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrQUGlZUUN3ME2xNk45QDd2IDFOwG0>Mlu5V2FPT0WU
TGBC24TKBMnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPjTWM2OD1zMz6wNlY4KCEQvF2=NEPFTlJUSU6JRWK=
SW626NYPrZ4x{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTF|LkK0PFUhKM7:TR?=MXnTRW5ITVJ?
ES6MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1q5XmlEPTB;MUOuNlUyOiBizszNMXPTRW5ITVJ?
NCI-H2029M4L4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLvTWM2OD1zMz64NVA5KCEQvF2=NVXh[pM6W0GQR1XS
RXF393NFnzfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPWTWM2OD1zMz65PVI4KCEQvF2=MXPTRW5ITVJ?
HMV-IIM4\Fc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnsPXlKSzVyPUG0MlA4QCBizszNMXnTRW5ITVJ?
EW-22NUPlRpA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rObmlEPTB;MUSuNVUxOiBizszNM2n0RnNCVkeHUh?=
AsPC-1M4fLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXEZ|dlUUN3ME2xOE42PjRiIN88US=>MWLTRW5ITVJ?
COLO-678NH7JW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTF2LkeyO|EhKM7:TR?=M1izUHNCVkeHUh?=
HCT-15M4Xrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLiTWM2OD1zND64PFU2KCEQvF2=NU\KfWk6W0GQR1XS
HCE-TNXXzRWZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PxbWlEPTB;MUSuPFg4PCBizszNMV;TRW5ITVJ?
SF539NUXM[mdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7SboxKSzVyPUG1MlA3PDNiIN88US=>MnHiV2FPT0WU
AU565MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzQbWttUUN3ME2xOU4zODl4IDFOwG0>MYLTRW5ITVJ?
JVM-2MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnyPVFmUUN3ME2xOU4zPjhzIDFOwG0>NFrGZXNUSU6JRWK=
CaR-1NVrwRW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTxfJhzUUN3ME2xOU41PDF{IDFOwG0>M4Cz[3NCVkeHUh?=
23132-87MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHCclJiUUN3ME2xOU45PDl3IDFOwG0>NGfxUVBUSU6JRWK=
A673Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmmxTWM2OD1zNT65OlM3KCEQvF2=NV;ZU|I2W0GQR1XS
KYSE-410NHnCcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInsTJNKSzVyPUG2MlAzQSBizszNNGj1e5hUSU6JRWK=
TE-9NXL4[ZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTF4LkC2NkAh|ryPNUHpeFd[W0GQR1XS
LU-139Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\qUVZZUUN3ME2xOk4yQDJ|IDFOwG0>NILIb|ZUSU6JRWK=
GCIYM1XPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1iyZ2lEPTB;MU[uNVkyPiBizszNNHr6RZhUSU6JRWK=
JEG-3MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjJXoFKUUN3ME2xOk4zPSBizszNNWDNXlNpW0GQR1XS
RT-112NFHNWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPTOJR6UUN3ME2xOk41OTR|IDFOwG0>Ml\HV2FPT0WU
COLO-680NNIfKVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzhW|BKSzVyPUG2MlUyODhiIN88US=>NIm4TZRUSU6JRWK=
LU-134-ANGrOfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1G0WGlEPTB;MU[uPVg6OyBizszNNF7lWW1USU6JRWK=
MFM-223NF\pfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTF5LkG1N|UhKM7:TR?=NUfBO5JvW0GQR1XS
SF126NH\GUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M331VGlEPTB;MUeuNVcxOSBizszNNFnvUYpUSU6JRWK=
NCI-H28MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2OycGlEPTB;MUeuNlA3PiBizszNNEHRW3VUSU6JRWK=
BFTC-905MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHKfGFKSzVyPUG3MlQ5OzJiIN88US=>NE\DbY9USU6JRWK=
SCC-9MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjQ[JNKSzVyPUG3MlYzQDViIN88US=>NWXxXVlTW0GQR1XS
KNS-62NInCRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4q3XWlEPTB;MUeuOlYzQSBizszNMUDTRW5ITVJ?
Hs-578-TNYPoOG9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jsd2lEPTB;MUeuPFE1QSBizszNNUjQe25GW0GQR1XS
D-336MGMmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlv3TWM2OD1zNz64Nlk1KCEQvF2=M4HRUHNCVkeHUh?=
NCI-H82NXm3TYwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEj3UnFKSzVyPUG4MlAyQDNiIN88US=>MVjTRW5ITVJ?
EFM-19NIfxXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHUdFFKSzVyPUG4MlA2PzdiIN88US=>NH;ud25USU6JRWK=
TGBC11TKBM1i1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rJ[GlEPTB;MUiuNVAzOSBizszNNWjn[m1kW0GQR1XS
HEC-1MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvaVHYyUUN3ME2xPE4zQTF6IDFOwG0>MYrTRW5ITVJ?
HuP-T3MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTF6LkW5NlkhKM7:TR?=NH;FRm5USU6JRWK=
SF268MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTF6Lk[3NFIhKM7:TR?=NFrhfJpUSU6JRWK=
COLO-792NUXNSmIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHFXndyUUN3ME2xPE44QTl5IDFOwG0>M2nxV3NCVkeHUh?=
HLEMkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoT5TWM2OD1zOD64N|MyKCEQvF2=MUXTRW5ITVJ?
A204MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jpVGlEPTB;MUiuPVE3PCBizszNNXnLcFZ2W0GQR1XS
CAL-72NHrnR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7DO4Y3UUN3ME2xPU4xQDd5IDFOwG0>NGezc4ZUSU6JRWK=
U031MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTF7LkS5NFkhKM7:TR?=MXnTRW5ITVJ?
FTC-133MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTF7LkmzNFQhKM7:TR?=MlL5V2FPT0WU
SK-MEL-28M1OwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrybY1KSzVyPUKwMlM4PjFiIN88US=>NF7aWmNUSU6JRWK=
KGNMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3uTWM2OD1{MD60Olk6KCEQvF2=MYTTRW5ITVJ?
HCC2998NXj2R5hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHj[YNUUUN3ME2yNU4{QTJ4IDFOwG0>NFzhfXNUSU6JRWK=
GOTONEjrW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jXN2lEPTB;MkGuOFg2KCEQvF2=MX\TRW5ITVJ?
AGSMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfhPVlKSzVyPUKxMlg1PTFiIN88US=>MVjTRW5ITVJ?
EW-13M3\kSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIX4bY1KSzVyPUKyMlExOjJiIN88US=>MXXTRW5ITVJ?
P12-ICHIKAWANG\tb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoezTWM2OD1{Mj6xOlA{KCEQvF2=MkHXV2FPT0WU
NCI-H1395M4TsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTJ{LkK5NFchKM7:TR?=NUewWHU1W0GQR1XS
A2058MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTJ{LkSzOEAh|ryPMYjTRW5ITVJ?
SH-4MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nkNGlEPTB;MkKuO|A1PSBizszNMX7TRW5ITVJ?
DoTc2-4510M2jpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTJ|Lk[0O|IhKM7:TR?=MYXTRW5ITVJ?
MMAC-SFNGjubopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vsUmlEPTB;MkOuOlkyOSBizszNMo\xV2FPT0WU
NCI-H510ANGXlTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzPOWlKSzVyPUKzMlc6OzliIN88US=>MWPTRW5ITVJ?
HDLM-2Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTJ2LkG0OkAh|ryPMWHTRW5ITVJ?
KINGS-1Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHPTWM2OD1{ND6yOFIhKM7:TR?=NHjIcHRUSU6JRWK=
NCI-H1648MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTJ2LkSwNlQhKM7:TR?=NXjNbHRtW0GQR1XS
HCC1187NUHKfWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XLXGlEPTB;MkWuNFI{PSBizszNNUTxWYxtW0GQR1XS
BALL-1M{D1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfPNoprUUN3ME2yOU4zODZ{IDFOwG0>NYDQbJg6W0GQR1XS
SBC-1M3zUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NID1eXhKSzVyPUK1MlI6QTNiIN88US=>NUD1VVh{W0GQR1XS
BFTC-909MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTJ3LkO1OVEhKM7:TR?=Mo\mV2FPT0WU
MOLT-13MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHJWFFQUUN3ME2yOU43PzR2IDFOwG0>MnfoV2FPT0WU
SW1990MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLlTWM2OD1{NT65OlU2KCEQvF2=MojMV2FPT0WU
DK-MGMkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjGNZQ1UUN3ME2yOk4xPDR|IDFOwG0>NH3tcY1USU6JRWK=
TE-8M2nPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlX2TWM2OD1{Nj6wOlY5KCEQvF2=NEjGUY1USU6JRWK=
BeckerNYWzcnZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVmyOXQyUUN3ME2yOk4yPTd2IDFOwG0>NULWO4lUW0GQR1XS
KYSE-70NYXQN|V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXqTos3UUN3ME2yOk42OzF5IDFOwG0>MmCxV2FPT0WU
MKN7NHroOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLVZmdKSzVyPUK3Mlc1PzliIN88US=>M2\ob3NCVkeHUh?=
D-392MGMl\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHWR4cxUUN3ME2yO{44Pjl2IDFOwG0>NWD2PYJ4W0GQR1XS
NH-12MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnWTldDUUN3ME2yPE4yOjJ7IDFOwG0>M2PqNXNCVkeHUh?=
EW-18MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjsfpJKSzVyPUK4MlIzOThiIN88US=>MW\TRW5ITVJ?
LCLC-97TM1NHfPbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPzOFBKSzVyPUK4MlI4PjJiIN88US=>NYTET3N6W0GQR1XS
NCI-H1770NG[2T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIT2dHhKSzVyPUK4MlM2PjZiIN88US=>Mn\WV2FPT0WU
BT-20MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonxTWM2OD1{OD6zOlg2KCEQvF2=MYPTRW5ITVJ?
DBTRG-05MGNHH0TVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjRTWM2OD1{OD60PFM5KCEQvF2=NH3Be|VUSU6JRWK=
HPAF-IINGD5T25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTJ6Lke3PUAh|ryPM1u0SXNCVkeHUh?=
SW837NHHMfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\yOZlRUUN3ME2yPU4{Ozh3IDFOwG0>NVLYWlVHW0GQR1XS
647-VMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1OwTWlEPTB;MkmuO|AxOyBizszNM2nRfHNCVkeHUh?=
J82MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfOd|RKSzVyPUK5MlgxOTNiIN88US=>NFK0dY1USU6JRWK=
MC116MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnSTWM2OD1|MD6wO|M{KCEQvF2=NVf4bG5XW0GQR1XS
NCI-H69MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTNyLk[wPVMhKM7:TR?=MVTTRW5ITVJ?
NB6MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fYbmlEPTB;M{GuN|YzQSBizszNNV\3b4pPW0GQR1XS
CAL-120NFH2VIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1r4TGlEPTB;M{KuOFMyPyBizszNM4TWU3NCVkeHUh?=
U-87-MGM4rRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTN|LkCyOVEhKM7:TR?=MnmzV2FPT0WU
NCI-H1304MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrrWYRKSzVyPUOzMlA{PTRiIN88US=>NE\mVFVUSU6JRWK=
YH-13MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3y5NGlEPTB;M{OuNlU{PSBizszNMVfTRW5ITVJ?
RMG-INYqxWZlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTN|LkSyPFUhKM7:TR?=NGXoUXRUSU6JRWK=
LU-65NUPnbnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTN2LkG0NFghKM7:TR?=M3H2OnNCVkeHUh?=
GB-1NIfqSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTN3LkC3NlkhKM7:TR?=M1jlPHNCVkeHUh?=
DU-4475MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTOTWM2OD1|NT6xOVU{KCEQvF2=NVT1W3RiW0GQR1XS
SBC-5MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPqTWM2OD1|Nj61PVAzKCEQvF2=NVPpWJFuW0GQR1XS
OE33NIDubGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jVXmlEPTB;M{euO|U4PyBizszNNWjJdXlrW0GQR1XS
C8166MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\NfWlEPTB;M{iuOVI3PyBizszNMYTTRW5ITVJ?
COLO-684NYHERmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnXTWM2OD1|OD63OFI5KCEQvF2=NH65UYZUSU6JRWK=
NCI-H1155NInINYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXkTWM2OD1|OT6wOFcyKCEQvF2=Mmn0V2FPT0WU
ATN-1NHHMV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTN7Lke3PVIhKM7:TR?=NHHiWGdUSU6JRWK=
KARPAS-299M2jocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXlTWM2OD1|OT64N|khKM7:TR?=MXnTRW5ITVJ?
KNS-81-FDMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moe0TWM2OD12MD6zOlA1KCEQvF2=NX;Jc3h7W0GQR1XS
NCI-H1563NIXhbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jKcmlEPTB;NEGuOVA{QSBizszNM2qxNXNCVkeHUh?=
NB14NUnOcIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLkUG5KSzVyPUSyMlczPjNiIN88US=>NEPCcFRUSU6JRWK=
COLO-800NXyxNnc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3wTWM2OD12Mj64OVE4KCEQvF2=NFz3NYNUSU6JRWK=
MS-1NIe5d4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVviT3VrUUN3ME20N{4xPDh|IDFOwG0>M1\5OnNCVkeHUh?=
OVCAR-8MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDjTWM2OD12Mz62PFA6KCEQvF2=MoLzV2FPT0WU
SK-PN-DWMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHnVoNKSzVyPUSzMlg4PzZiIN88US=>M17IVXNCVkeHUh?=
G-402MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTR|LkmwNFYhKM7:TR?=MkHnV2FPT0WU
NCI-H2291M1P0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13kUGlEPTB;NESuPFAyPyBizszNNVHYc4pCW0GQR1XS
PC-3NI\JcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTUTWM2OD12NT64NFI{KCEQvF2=M{XTeHNCVkeHUh?=
NCI-H1581MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfLTWM2OD12NT65PFg6KCEQvF2=M{\oO3NCVkeHUh?=
SW1116NVzZUHNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnr2TWM2OD12Nz6wNVgzKCEQvF2=M1\5VHNCVkeHUh?=
ZR-75-30MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NICwN4xKSzVyPUS3MlAzOzliIN88US=>MWDTRW5ITVJ?
OCI-AML2NIq1OVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHr2e3RKSzVyPUS3MlA6OThiIN88US=>NIf5eWVUSU6JRWK=
MDA-MB-231MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPYb2FKSzVyPUS3MlYzPDliIN88US=>NIrPRpJUSU6JRWK=
ES3MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTrTWM2OD12OD6zOVI6KCEQvF2=M{n1TnNCVkeHUh?=
NCI-H630M4ThUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHWOnduUUN3ME20PU4yPzR{IDFOwG0>NF3QU|BUSU6JRWK=
OE19MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LP[GlEPTB;NEmuNlkxOiBizszNMlTVV2FPT0WU
NCI-H1573MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHwSFFKSzVyPUS5MlY5PjFiIN88US=>NInZNVhUSU6JRWK=
EW-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PocGlEPTB;NEmuPVA5PCBizszNMXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02810990 Not yet recruiting Chronic Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto September 2016 Phase 2
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer March 2016 Phase 2
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02546375 Active, not recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates July 2015 --

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) ic50 | Bosutinib (SKI-606) price | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) solubility dmso | Bosutinib (SKI-606) purchase | Bosutinib (SKI-606) manufacturer | Bosutinib (SKI-606) research buy | Bosutinib (SKI-606) order | Bosutinib (SKI-606) mouse | Bosutinib (SKI-606) chemical structure | Bosutinib (SKI-606) mw | Bosutinib (SKI-606) molecular weight | Bosutinib (SKI-606) datasheet | Bosutinib (SKI-606) supplier | Bosutinib (SKI-606) in vitro | Bosutinib (SKI-606) cell line | Bosutinib (SKI-606) concentration | Bosutinib (SKI-606) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us